The recent Cyclospora outbreak has pushed food safety, traceability, and testing to the top of investors’ watchlists. When regulators, distributors, and restaurant suppliers come under pressure, attention often shifts to companies that help monitor, test, and verify what moves through the food supply chain. This article looks at how that news may affect a handful of Food Safety & Testing Companies, and why some stocks could be positioned as potential beneficiaries of higher scrutiny and compliance spending. Ahead, you will see 3 stocks exposed to this news event and how each might fit into your watchlist.

GeneDx Holdings (WGS)

Overview: GeneDx Holdings is a genomics company that provides genetic testing services focused on pediatric and rare diseases, using whole exome and whole genome sequencing to help doctors pinpoint underlying conditions. It also offers data services and an AI based platform that supports next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

Operations: GeneDx generates about US$437.5 million from its Gene Dx segment and a US$5.2 million segment adjustment, with all reported revenue of roughly US$442.7 million coming from the United States.

Market Cap: US$1.75b

GeneDx Holdings gives investors a way to tap into rising demand for genomics and AI based diagnostics, while also sitting squarely in the conversation around better testing and traceability after outbreaks such as Cyclospora. The company is still loss making and carries funding and reimbursement risks, as highlighted by its recent class action and higher risk capital structure. Analysts currently project a potential shift to profitability within 3 years. Some investors exited after guidance cuts and a revenue miss, which has weakened sentiment and may create an entry point for those who see value in its rare disease data, AI platform, and payer coverage initiatives.

Sentiment around GeneDx Holdings has swung hard, yet its rare disease data and AI platform could be the real story driver. Check the 3 key rewards and 1 important major warning sign that might flip the usual bear case on its head

Prenetics Global (PRE)

Overview: Prenetics Global is a consumer health company that sells science backed health and longevity products under its IM8 brand, and runs CircleDNA, a consumer genetic testing service that uses sequencing technology to provide personalized health, wellness, and lifestyle reports.

Market Cap: US$315.4 million

Investors watching the food safety theme may want to pay attention to Prenetics Global because it sits at the crossroads of health diagnostics, genetic testing, and fast growing subscription based wellness. IM8 is already scaling on a recurring revenue model, supported by a high subscription mix and a focus on premium, science backed supplements. Recent partnerships, such as its tie up with Inter Miami CF, highlight how the brand is trying to build global recognition quickly. At the same time, Prenetics is still loss making, has diluted shareholders, and carries execution risk as it pursues ambitious growth targets and manages a Bitcoin treasury. That mix of strong top line ambitions and balance sheet and governance questions may make Prenetics worth a closer look for investors focused on food safety and health testing themes.

Subscription fueled health and genetics is where Prenetics Global wants to accelerate, but the real question is how that pitch stacks up once you factor in dilution, Bitcoin exposure, and execution risk in the analysis report for Prenetics Global

BillionToOne (BLLN)

Overview: BillionToOne is a precision diagnostics company that uses its molecular counting platform to measure individual DNA molecules and improve disease detection. It currently focuses on non invasive prenatal screening through its UNITY suite and liquid biopsy cancer tests like Northstar Select and Northstar Response, which track tumor mutations and treatment response from blood samples instead of tissue biopsies.

Operations: BillionToOne generates about US$354.5 million in revenue from Medical Labs and Research services, all reported from the United States.

Market Cap: US$5.8b

BillionToOne operates at the intersection of prenatal screening, oncology and high precision liquid biopsy. This positioning makes its diagnostics platform especially notable as regulators and food distributors focus more closely on early detection and lab capabilities after incidents like the Cyclospora outbreak. The company reports profitability, with expanding reimbursement coverage and clinical data indicating that Northstar Response can flag progression earlier than imaging across multiple tumor types. At the same time, a high P/S multiple, reliance on higher risk funding sources and a history of one off losses present risks that need to be weighed carefully. For investors willing to conduct in depth research, BillionToOne combines strong test data, growing visibility and significant execution questions that may merit further analysis.

BillionToOne’s mix of prenatal screening, oncology tests and reported profitability looks like a story investors have not fully priced in yet, and the full picture of funding risks and execution upside sits inside the analysis report for BillionToOne

The three stocks covered here are just a starting point, and the full Food Safety & Testing Companies screener on Simply Wall St surfaced 16 more companies with equally compelling narratives around traceability, diagnostics, compliance, and supply chain monitoring in the Food Safety & Testing Companies screener. You can use Simply Wall St to identify and analyze the specific catalysts that matter most to you, then filter by the narratives in this article so you can focus on the opportunities in this theme that best align with your own view.

Take Control of Your Investment Journey

If BillionToOne or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Catch On

Fresh ideas can move fast, and some entry points may appear before momentum, headlines, and valuations start increasing. Consider researching early, rather than responding only after trends develop.

• Spot potential early movers in smaller companies by scanning 20 elite penny stocks with strong financials that have been filtered for stronger balance sheets rather than hype driven stories.
• Target stable income ideas with the 9 dividend fortresses that focuses on companies aiming to sustain higher yields while many investors are still pursuing pure growth stories.
• Hunt for resilient opportunities using the 84 resilient stocks with low risk scores that highlights businesses screened for lower risk scores before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.